{"id":"NCT01465997","sponsor":"UCB BIOSCIENCES GmbH","briefTitle":"Evaluating Long Term Safety of Lacosamide (LCM) to Carbamazepine Controlled-release (CBZ-CR); Initial Monotherapy in Epilepsy Subjects 16 Years and Older","officialTitle":"A Multicenter, Double-blind, Double-dummy, Follow up Study Evaluating the Long-term Safety of Lacosamide in Comparison With Controlled-release Carbamazepine Used as Monotherapy in Subjects With Partial-onset or Generalized Tonic-clonic Seizures ≥16 Years of Age Coming From the SP0993 Study.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-05","primaryCompletion":"2017-01","completion":"2017-01","firstPosted":"2011-11-07","resultsPosted":"2017-08-02","lastUpdate":"2018-07-18"},"enrollment":551,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Epilepsy","Monotherapy"],"interventions":[{"type":"DRUG","name":"Lacosamide","otherNames":["VIMPAT film-coated tablets"]},{"type":"DRUG","name":"Carbamazepine-Controlled Release (CBZ-CR)","otherNames":["Tegretol® Retard Tablets 200 mg"]}],"arms":[{"label":"Lacosamide","type":"EXPERIMENTAL"},{"label":"Carbamazepine-Controlled Release (CBZ-CR)","type":"ACTIVE_COMPARATOR"}],"summary":"Compare safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR) as monotherapy in newly or recently newly diagnosed subjects with primary safety variables including spontaneous reports of Adverse Events (AEs), withdrawal of subjects due to AEs, reporting of Serious AEs (SAEs).","primaryOutcome":{"measure":"Number of Subjects With at Least One Treatment-emergent Adverse Event (AE) During the Treatment Phase (Maximum of 3.5 Years)","timeFrame":"Up to 3.5 Years (Duration of the Treatment Phase)","effectByArm":[{"arm":"Lacosamide (SS)","deltaMin":181,"sd":null},{"arm":"Carbamazepine-Controlled Release (CBZ-CR) (SS)","deltaMin":182,"sd":null}],"pValues":[]},"eligibility":{"minAge":null,"sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":6},"locations":{"siteCount":150,"countries":["United States","Australia","Belgium","Bulgaria","Canada","Czechia","Finland","France","Germany","Greece","Hungary","Italy","Japan","Latvia","Lithuania","Mexico","Philippines","Poland","Portugal","Romania","Russia","Slovakia","South Korea","Spain","Sweden","Switzerland","Thailand","Ukraine","United Kingdom"]},"refs":{"pmids":["34265173"],"seeAlso":["http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm"]},"adverseEventsSummary":{"seriousAny":{"events":32,"n":279},"commonTop":["Nasopharyngitis","Headache","Dizziness"]}}